Efficacy and Safety Analysis of Recombinant Factor VIIa in Severe Post-partum Hemorrhage
Authors:
- Camila Caram-DeelderCCCamila Caram-Deelder
- Hellen McKinnon EdwardsHEHellen McKinnon Edwards
- Jarmila A ZdanowiczJZJarmila A Zdanowicz
- Thomas Van Den AkkerTAThomas Van Den Akker
- Camilla BirkegårdCBCamilla Birkegård
- Jan BlatnýJBJan Blatný
- Johanna Van der BomJBJohanna Van der Bom
- Giuseppe ColucciGCGiuseppe Colucci
- Derek Van DuurenDDDerek Van Duuren
- Nan Van GelovenNGNan Van Geloven
- Dacia HenriquezDHDacia Henriquez
- Marian KnightMKMarian Knight
Preprint
- 4 March 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background: Despite a range of available treatments, there is a remaining unmet need for patients with severe post-partum hemorrhage (sPPH). Objective: This manuscript evaluated efficacy and safety of recombinant activated factor VIIa (rFVIIa) in sPPH management. Methods: An open-label, multi-center, randomized controlled trial (RCT; NCT00370877) and four observational studies (OS; OS-1 [NCT04723979], OS-2, OS-3 and OS-4) were analyzed regarding efficacy (need for subsequent invasive procedures, including uterine compression sutures, uterine or iliac artery ligation, arterial embolization or hysterectomy) and safety (incidence of thromboembolic events [TE] and maternal mortality) of rFVIIa for sPPH. The RCT, and OS-1 and OS-2, included a control group of women who did not receive rFVIIa (with propensity score-matching used in OS-1 and OS-2), whereas OS-3 and OS-4 provided descriptive data for rFVIIa exposed women only. Results: A total of 446 women exposed to rFVIIa and 1,717 non-exposed controls were included. In the RCT, fewer rFVIIa exposed women (50% [21/42]) had an invasive procedure versus non-exposed women (91% [38/42]; odds ratio 0.11, 95% confidence interval 0.03–0.35). In OS-1, more rFVIIa exposed women (58% [22/38]) had an invasive procedure versus non-exposed women (35% [13.3/38]; odds ratio 2.46, 95% confidence interval 1.06–5.99). In OS-2, 17% (3/18) of rFVIIa exposed women and 32% (5.6/17.8) of non-exposed women had an invasive procedure (odds ratio 0.33, 95% confidence interval 0.03–1.75). Across all included women, TEs occurred in 1.5% (0.2% arterial and 1.2% venous) of rFVIIa exposed women and 1.6% (0.2% arterial and 1.4% venous) of non-exposed women with available data. Conclusions: The positive treatment effect of rFVIIa in the RCT was not confirmed in the OS. However, the safety analysis did not show any increased incidence of TEs with rFVIIa treatment.Keywords
All Related Versions
- Version 1, 2024-03-04, Preprints
- Published version: Journal of Clinical Medicine, 13 (9), 2656.
This publication has 28 references indexed in Scilit:
- Association of Timing of Plasma Transfusion With Adverse Maternal Outcomes in Women With Persistent Postpartum HemorrhageJAMA Network Open, 2019
- Postpartum blood transfusion and hemorrhage as independent risk factors for venous thromboembolismThrombosis Research, 2018
- Peripartum Haemorrhage, Diagnosis and Therapy. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 015/063, March 2016)Geburtshilfe und Frauenheilkunde, 2018
- Emergency hysterectomy for life-threatening postpartum haemorrhage: Risk factors and psychological impactGynécologie Obstétrique & Fertilité, 2015
- Fertility rate and subsequent pregnancy outcomes after conservative surgical techniques in postpartum hemorrhage: 15 years of literatureFertility and Sterility, 2013
- Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaCochrane Database of Systematic Reviews, 2012
- Severe postpartum haemorrhage treated with recombinant activated Factor VII in 80 Czech patients: analysis of the UniSeven registryInternational Journal of Obstetric Anesthesia, 2011
- The Use of Recombinant Activated FVII in Postpartum HemorrhageClinical Obstetrics and Gynecology, 2010
- Predictors of Failed Pelvic Arterial Embolization for Severe Postpartum HemorrhageObstetrics & Gynecology, 2009
- Use of Recombinant Activated Factor VII in Primary Postpartum Hemorrhage: The Northern European Registry 2000-2004Obstetric Anesthesia Digest, 2008